Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJan 22, 2020BACLOFEN 2000MCG/MLLack of sterility assurance.Assurance Infusion · D-0676-2020Class IITerminatedJan 22, 2020BAC 800MCG/BUP 6.7MG/CLON 600 MCG/FENT 850MCG/MORP 20MG INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0675-2020Class IITerminatedJan 22, 2020BAC 50MCG/ HYDROM 10MG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0674-2020Class IITerminatedJan 22, 2020BAC 400MCG/BUP 20MG/HYDROM 15MG/SUF 1000MCG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0673-2020Class IITerminatedJan 22, 2020BAC 4000MCG /FENT 600MCG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0672-2020Class IITerminatedJan 22, 2020BAC 250MCG/ /FENT 3500MCG/ /MORP 25MG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0671-2020Class IITerminatedJan 22, 2020BAC 2400MCG/ FENT 2600MCG/ MORP 3600MCG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0670-2020Class IITerminatedJan 22, 2020BAC 225MCG/ BUP 4.5MG/ CLON 9MCG/ MORP 3MG/ML ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0669-2020Class IITerminatedJan 22, 2020BAC 200MCG/BUP22MG/CLON210MCG/HYDROM 15MG/SUF800MCG/ML ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0668-2020Class IITerminatedJan 22, 2020BAC 200MCG/ CLONI 250MCG/ MORP 10MG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0667-2020Class IITerminatedJan 22, 2020BAC 160MCG/HYDROM 16MG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0666-2020Class IITerminatedJan 22, 2020BAC 15MCG/HYDROM 15MG/ML INJ in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0665-2020Class IITerminatedJan 22, 2020BAC 150 mcg/BUP 2 mg/Hydrom 15 mg/Morp 20 mg/SUF 650 mcg/mL Inj. in 20 mL syringe Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0664-2020Class IITerminatedJan 22, 2020Autologous Serum 20% Eye Drops in 3 mL droppers Assurance InfusionLack of sterility assurance.Assurance Infusion · D-0663-2020Class IITerminatedJan 22, 2020Alprostadil 40 mcg/mLLack of sterility assurance.Assurance Infusion · D-0662-2020Class IITerminatedJan 22, 2020Dutasteride CapsulesFailed Impurities/Degradation Specifications: High out of specification results for related compounds.AVKARE Inc. · D-0661-2020Class IITerminatedJan 22, 2020Sumatriptan Succinate TabletsFailed Impurities/Degradation Specifications; out-of-specification results obtained for related substance.Sun Pharmaceutical Industries, Inc. · D-0660-2020Class IITerminatedJan 22, 2020Sumatriptan Succinate TabletsFailed Impurities/Degradation Specifications; out-of-specification results obtained for related substance.Sun Pharmaceutical Industries, Inc. · D-0659-2020Class IITerminatedJan 22, 2020Ketorolac Tromethamine InjectionPresence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)Hikma Pharmaceuticals USA Inc. · D-0658-2020Class ITerminatedJan 22, 2020Panther Platinum 30000 CapsulesMarketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfilMotto International Corp · D-0657-2020Class ITerminatedJan 22, 2020Rhino 7 Platinum 30000 CapsulesMarketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfilMotto International Corp · D-0656-2020Class ITerminatedJan 22, 2020Stallion Platinum 30000 Capsules in blueMarketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfilMotto International Corp · D-0655-2020Class ITerminatedJan 22, 2020Bull Platinum 30000 CapsulesMarketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfilMotto International Corp · D-0654-2020Class IIITerminatedJan 15, 2020SURE 48hr Confidence Unscented Original Solid Anti-Perspirant & Deodorant Net Wt 2.7 ozLabeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product.Idelle Labs · D-0786-2020Class IIITerminatedJan 15, 2020SURE 48hr Confidence Regular Original Solid Anti-Perspirant & Deodorant Net Wt 2.7 ozLabeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product.Idelle Labs · D-0785-2020Class IIITerminatedJan 15, 2020SURE 48hr Confidence Nourishing Coconut invisible solid Antiperspirant & Deodorant Net Wt 2.6 ozLabeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product.Idelle Labs · D-0784-2020Class IIITerminatedJan 15, 2020SURE 48 hr Confidence Unscented invisible solid Anti-Perspirant & DeodorantLabeling Product Contains Undeclared API: Active Ingredient on label is not the active ingredient in the product.Idelle Labs · D-0783-2020Class IITerminatedJan 15, 2020Estriol, USPFailed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.Asclemed USA Inc. dba Enovachem Pharmaceuticals · D-0652-2020Class IITerminatedJan 15, 2020Estriol, USPFailed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.Asclemed USA Inc. dba Enovachem Pharmaceuticals · D-0651-2020Class IITerminatedJan 15, 2020Estriol, USPFailed Impurities/Degradation Specifications: Additional testing found Out of Specification impurity test results.Asclemed USA Inc. dba Enovachem Pharmaceuticals · D-0650-2020Class IITerminatedJan 15, 2020Ranitidine Capsules 150 mgCGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIAppco Pharma LLC · D-0649-2020Class IITerminatedJan 15, 2020Ranitidine Capsules 300 mgCGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIAppco Pharma LLC · D-0648-2020Class IITerminatedJan 15, 2020Ranitidine 150 mg tabletsCGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIAAA Pharmaceutical, Inc. · D-0646-2020Class IITerminatedJan 15, 2020Ranitidine 150 mg tabletsCGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIAAA Pharmaceutical, Inc. · D-0645-2020Class IIOngoingJan 15, 2020Glenmark Ranitidine Tablets USP 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Glenmark Pharmaceuticals Inc., USA · D-0644-2020Class IIOngoingJan 15, 2020Glenmark Ranitidine Tablets USP 300 mgCGMP Deviations: Presence of NDMA impurity detected in product.Glenmark Pharmaceuticals Inc., USA · D-0643-2020Class IIOngoingJan 15, 2020Glenmark Ranitidine Tablets USP 300 mgCGMP Deviations: Presence of NDMA impurity detected in product.Glenmark Pharmaceuticals Inc., USA · D-0642-2020Class IIOngoingJan 15, 2020Glenmark Ranitidine Tablets USP 300 mgCGMP Deviations: Presence of NDMA impurity detected in product.Glenmark Pharmaceuticals Inc., USA · D-0641-2020Class IIOngoingJan 15, 2020Glenmark Ranitidine Tablets USP 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Glenmark Pharmaceuticals Inc., USA · D-0640-2020Class IIOngoingJan 15, 2020Glenmark Ranitidine Tablets USP 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Glenmark Pharmaceuticals Inc., USA · D-0639-2020